BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9619633)

  • 1. Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol.
    Hayes A; Williams DA
    J Neurol Sci; 1998 May; 157(2):122-8. PubMed ID: 9619633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term clenbuterol administration alters the isometric contractile properties of skeletal muscle from normal and dystrophin-deficient mdx mice.
    Hayes A; Williams DA
    Clin Exp Pharmacol Physiol; 1994 Oct; 21(10):757-65. PubMed ID: 7867226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice.
    Lynch GS; Cuffe SA; Plant DR; Gregorevic P
    Neuromuscul Disord; 2001 Apr; 11(3):260-8. PubMed ID: 11297941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Power output of fast and slow skeletal muscles of mdx (dystrophic) and control mice after clenbuterol treatment.
    Lynch GS; Hinkle RT; Faulkner JA
    Exp Physiol; 2000 May; 85(3):295-9. PubMed ID: 10825417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sternohyoid muscle fatigue properties of dy/dy dystrophic mice, an animal model of merosin-deficient congenital muscular dystrophy.
    van Lunteren E; Moyer M
    Pediatr Res; 2003 Oct; 54(4):547-53. PubMed ID: 12840158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clenbuterol reduces soleus muscle fatigue during disuse in aged rats.
    Chen KD; Alway SE
    Muscle Nerve; 2001 Feb; 24(2):211-22. PubMed ID: 11180204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contractile properties of clenbuterol-treated mdx muscle are enhanced by low-intensity swimming.
    Hayes A; Williams DA
    J Appl Physiol (1985); 1997 Feb; 82(2):435-9. PubMed ID: 9049721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of voluntary wheel running on the properties of dystrophic mouse muscle.
    Hayes A; Williams DA
    J Appl Physiol (1985); 1996 Feb; 80(2):670-9. PubMed ID: 8929614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice.
    Dupont-Versteegden EE; Katz MS; McCarter RJ
    Muscle Nerve; 1995 Dec; 18(12):1447-59. PubMed ID: 7477069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle.
    Zeman RJ; Peng H; Danon MJ; Etlinger JD
    Muscle Nerve; 2000 Apr; 23(4):521-8. PubMed ID: 10716762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the beta 2-adrenergic agonist clenbuterol on the growth of fast- and slow-twitch skeletal muscle of the dystrophic (C57BL6J dy2J/dy2J) mouse.
    Agbenyega ET; Morton RH; Hatton PA; Wareham AC
    Comp Biochem Physiol C Pharmacol Toxicol Endocrinol; 1995 Jul; 111(3):397-403. PubMed ID: 8564781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of neonatal denervation-reinnervation on the functional capacity of a 129ReJ dy/dy murine dystrophic muscle.
    Hermanson JW; Moschella MC; Ontell M
    Exp Neurol; 1988 Nov; 102(2):210-6. PubMed ID: 3181359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clenbuterol, a beta 2-agonist, retards wasting and loss of contractility in irradiated dystrophic mdx muscle.
    Zeman RJ; Zhang Y; Etlinger JD
    Am J Physiol; 1994 Sep; 267(3 Pt 1):C865-8. PubMed ID: 7943213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of body composition by clenbuterol in normal and dystrophic (mdx) mice.
    Rothwell NJ; Stock MJ
    Biosci Rep; 1985 Sep; 5(9):755-60. PubMed ID: 4084674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EDL and soleus muscles of the C57BL6J/dy2j laminin-alpha 2-deficient dystrophic mouse are not vulnerable to eccentric contractions.
    Head SI; Bakker AJ; Liangas G
    Exp Physiol; 2004 Sep; 89(5):531-9. PubMed ID: 15184359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced fatigue in diaphragm muscle of merosin-deficient DY/DY dystrophic mice.
    van Lunteren E; Moyer M
    Respiration; 2003; 70(6):636-42. PubMed ID: 14732796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Year-long clenbuterol treatment of mice increases mass, but not specific force or normalized power, of skeletal muscles.
    Lynch GS; Hinkle RT; Faulkner JA
    Clin Exp Pharmacol Physiol; 1999 Feb; 26(2):117-20. PubMed ID: 10065331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscular transverse relaxation time measurement by magnetic resonance imaging at 4 Tesla in normal and dystrophic dy/dy and dy(2j)/dy(2j) mice.
    Tardif-de Géry S; Vilquin J; Carlier P; Raynaud JS; Wary C; Schwartz K; Leroy-Willig A
    Neuromuscul Disord; 2000 Oct; 10(7):507-13. PubMed ID: 10996783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contractile function and low-intensity exercise effects of old dystrophic (mdx) mice.
    Hayes A; Williams DA
    Am J Physiol; 1998 Apr; 274(4):C1138-44. PubMed ID: 9575811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in isometric contractile properties of fast-twitch and slow-twitch skeletal muscle of C57BL/6J dy2J/dy2J dystrophic mice during postnatal development.
    Bressler BH; Jasch LG; Ovalle WK; Slonecker CE
    Exp Neurol; 1983 May; 80(2):457-70. PubMed ID: 6840250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.